Release of Data Sample Clauses

Release of Data. The Participating Generating Facility authorizes the Company to release to the California Energy Commission (“CEC”), the CAISO, and/or the CPUC information regarding the Participating Generating Facility, including the characteristics of its Generating Facility, and any other relevant operational characteristics as are requested from time to time pursuant to the CEC’s, CAISO’s, or CPUC’s rules and regulations.
AutoNDA by SimpleDocs
Release of Data. Release of data will be accomplished in the manner prescribed by lead OTA directives, with equal access given to participating OTAs. Data will be shared among the test team regardless of OTA affiliation. Exceptions will be handled by lead OTA directives.
Release of Data. From time to time, Customer may instruct or authorize ML Pro or another BofAML Entity to release information relating to Customer, the Accounts or Customer transactions to third-parties, including, without limitation, service bureaus and other service providers. No BofAML Entity shall be held liable for any use or misuse of such information by such third parties or any parties who receive such information, directly or indirectly, from or through such third parties.
Release of Data. CPARS information is considered business sensitive and will not be released except; (1) to other Federal procurement activities which request it; (2) when the Government must release pursuant to a Freedom of Information Act (FOIA) request; or (3) when prior written consent is requested and obtained from the Contractor. The guidebook for CPARS is electronically accessible at the following address: xxxxx://xxx.xxxxx.xxx/ CLAUSES INCORPORATED BY REFERENCE 252.232-7003 Electronic Submission of Payment Requests and Receiving Reports JUN 2012 CLAUSES INCORPORATED BY FULL TEXT 252.232-7006 WIDE AREA WORKFLOW PAYMENT INSTRUCTIONS (MAY 2013)
Release of Data. From time to time, Customer may instruct or authorize Prime Broker or another BofAML Entity to release information relating to Customer, the Accounts or Customer transactions to third-parties, including, without limitation, Executing Brokers, service bureaus and other service providers. No BofAML Entity shall be held liable for any use or misuse of such information by such third parties or any parties who receive such information, directly or Indirectly, from or through such third parties.
Release of Data. (1) CMS may re- lease the minimum data necessary for a given purpose from the data collected under paragraph (f)(3) of this section to Federal executive branch agencies, States, and external entities in accord- ance with the following:
AutoNDA by SimpleDocs
Release of Data. Except as may be exempt from disclosure under applicable law, the Seller authorizes the Buyer to release to any regulatory authority having jurisdiction over the Facility or a Party, or to any request made pursuant to the California Constitution or the California Public Records Act, information regarding the Facility, including the Seller’s name and location, operational characteristics, the Term of this Agreement, the Facility resource type, the scheduled Commercial Operation Date, the actual Commercial Operation Date, the Contract Capacity, payments made to the Seller and Energy production information. The Seller acknowledges that this information may be made publicly available.
Release of Data. In the event Lessee assigns its interest in this Lease or upon the written request of Lessor within six months of Lessee's termination of this Lease, Lessee shall supply to Lessor copies of any noninterpretive core analysis, drill hole logs, and assays taken from the Property ("Data"). Lessee makes no representation or warranty as to the accuracy or completeness of any such Data and shall not be liable on account of any use thereof by Lessor or any other person. Lessee shall not be responsible for any loss or destruction of drill core.
Release of Data. The Company shall publicly announce the top-line data from the Company’s Phase II(b) clinical trial evaluating the use of CPP-109 (the Company’s formulation of vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction as soon as reasonably practicable after the Effective Date.
Time is Money Join Law Insider Premium to draft better contracts faster.